- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.03. | NSE - LumiraDx Ltd - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 5 | SEC Filings | ||
| 20.03. | Delisting of Securities of Latch, Inc.; Eloxx Pharmaceuticals, Inc.; Collective Audience, Inc. (f.k.a., ABRIC SPAC I); SeqLL Inc.; Nemaura Medical Inc.; LumiraDx Limited; Cemtrex Inc.; COMSovereign Holding Corp.; Global System Dynamics; Arrival ... | 102 | GlobeNewswire (Europe) | NEW YORK" March 20, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock and warrants of Latch, Inc. Latch, Inc.'s securities were suspended on August... ► Artikel lesen | |
| 06.02. | LumiraDx Ltd - 6-K, Report of foreign issuer | 7 | SEC Filings | ||
| 08.01. | Why Is LumiraDx (LMDX) Stock Down 13% Today? | 11 | InvestorPlace | ||
| 08.01. | Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket | 4 | Benzinga.com | ||
| 06.01. | LumiraDx to be delisted from Nasdaq on January 9 | 4 | Investing.com | ||
| 05.01. | LumiraDx says its securities will be suspended from trading on Nasdaq | 2 | Seeking Alpha | ||
| 05.01. | LumiraDx Inc: LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th | 276 | GlobeNewswire (Europe) | LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the "Company") today announced that it has received notification from The Nasdaq Stock Market LLC ("Nasdaq") that its securities... ► Artikel lesen | |
| 02.01. | Roche to pick up LumiraDx's point-of-care tests through $350M deal | 19 | FierceBiotech | ||
| 02.01. | Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology | 12 | Zacks | ||
| 02.01. | Why LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket | 3 | Benzinga.com | ||
| 02.01. | Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M | 11 | Benzinga.com | ||
| 02.01. | LumiraDx falls on agreement with Roche to sell assets | 15 | Seeking Alpha | ||
| 02.01. | BioPharma Credit to fund LumiraDx ahead of acquisition by Roche | 13 | Alliance News | ||
| 02.01. | LumiraDx, Sacks Parente Golf And 3 Stocks To Watch Heading Into Tuesday | 2 | Benzinga.com | ||
| 01.01. | Roche bolsters diagnostics with $295m LumiraDx deal | 12 | pharmaphorum | ||
| 31.12.23 | Roche to acquire LumiraDx's Point of Care technology for $295 million plus up to $55 million | 7 | POST Online Media | ||
| 30.12.23 | Roche to buy part of LumiraDx diagnostics platform for $295 million | 21 | Reuters | ||
| 29.12.23 | LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche | 6 | RTTNews | ||
| 29.12.23 | F. Hoffmann-La Roche Ltd: Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform | 775 | GlobeNewswire (Europe) | The transformative point of care solution will complement Roche's centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease... ► Artikel lesen |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORPEA | 12,306 | +0,67 % | EMEIS PURSUES ITS REFOUNDATION: 2023 Consolidated Financial Results of ORPEA S.A. | Significant improvement in non-financial indicators, with major advances for employees, residents and patients
Health and safety: decline in the work-related accident frequency rate, at 24.8... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 2,914 | 0,00 % | Tempest Therapeutics: Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications | TPST-1120, a first-in-class, oral, selective PPAR? antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data... ► Artikel lesen | |
| NANO-X IMAGING | 8,600 | -5,18 % | Nano-X Imaging LTD.: Nanox Announces AI Software Increases Identification of Patients with Vertebral Compression Fractures, an early sign of Osteoporosis, Up to Six-Fold | - According to early findings in the ADOPT study, Nanox.AI software improves detection of key risk factor for osteoporosis, outperforming UK National Health Service national average - Findings... ► Artikel lesen | |
| BUTTERFLY NETWORK | 0,751 | -8,72 % | Butterfly Network expands maternal ultrasound efforts across Africa | ||
| INTELLIGENT BIO SOLUTIONS | 3,870 | 0,00 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Third Quarter and Nine-Month Revenue Results | NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| GOODRX | 6,690 | -0,59 % | GoodRx Reports Fourth Quarter and Full Year 2023 Results | SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("GoodRx" or the "Company"), the leading destination for prescription savings in the U.S., has released its financial... ► Artikel lesen | |
| JOINT CORP | 12,200 | +2,35 % | The Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 Results | ||
| CARMAT | 3,830 | +0,79 % | CARMAT Announces Its Participation in Several Scientific and Investor Conferences During the Second Quarter of 2024 | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| HYPERFINE | 0,830 | +2,47 % | Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results | GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable... ► Artikel lesen | |
| PROGYNY | 32,700 | +2,57 % | Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care | ||
| BIOMERICA | 0,730 | -1,36 % | Biomerica, Inc.: Biomerica Reports Third Quarter 2024 Financial Results | Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27 from $0.40 Amidst Sales Force Expansion for the Nine Months in Fiscal 2024 InFoods IBS Positive Clinical Data to be Presented... ► Artikel lesen | |
| MIMEDX | 6,290 | +2,11 % | MiMedx Group, Inc: MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30 | ||
| ATRICURE | 23,200 | -0,81 % | AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management | ||
| ATRION | 362,00 | -2,69 % | Dividendenbekanntmachungen (14.03.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN PLC GB00BF8Q6K64 0,073 GBP 0,0853 EUR ABRDN PLC ADR US00108N1000 0,3203 USD 0,2925 EUR ACCO BRANDS CORPORATION US00081T1088 0... ► Artikel lesen | |
| OUTSET MEDICAL | 2,320 | +3,11 % | Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis |
LUMIRADX LIMITED gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (-1,25 %) liegt der Kurs bei 0,016 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
